Overview of Feniallerg

Property	Description
Active ingredient	Dimetindene maleate
Form	Oral drops (solution), Topical gel
Pharmacological class	First-generation H1-receptor antagonist (Antihistamine)
Common use	Symptomatic relief of pruritus and allergy manifestations
Origin	Synthetic

What Type of Medicine is Feniallerg and What Does it Contain?

Feniallerg is a synthetic pharmaceutical preparation containing the active component, dimetindene maleate. It is classified as an antihistamine, specifically identified as a first-generation H1-receptor antagonist. The medicinal activity is singularly attributed to dimetindene, which is a small molecule of synthetic origin used to counter the effects of histamine in the body. The compound's efficacy as an anti-allergic agent is clinically recognized for its ability to quickly interfere with the immediate actions of histamine.

In What Forms is Dimetindene Available?

The active ingredient dimetindene is made available in different forms depending on the target relief area, including oral drops (solution) and a topical gel. These distinct drug forms offer flexibility: the oral solution is generally suitable for systemic relief of widespread allergic symptoms, while the gel is applied for localized relief of skin reactions, demonstrating a versatile approach to the oral or topical routes of administration. This availability in both forms is a key feature, differentiating its application versatility compared to many other systemic antihistamines.

What is the General Purpose of Feniallerg?

The general therapeutic purpose of Feniallerg is to provide rapid, symptomatic relief from the physical discomfort of allergic conditions. As an H1-receptor antagonist, its core action counters the effects of histamine, a substance that triggers allergy symptoms such as pruritus (itching) and localized swelling. Dimetindene exhibits a dual function, characterized by its ability to both block histamine and provide local anaesthetic effects. This dual mechanism is particularly beneficial for common situations like relieving the intense itching associated with a widespread rash or a sudden allergic skin manifestation.

What side effects are possible with Feniallerg?

Possible side effects and safety information

The safety profile for Feniallerg (dimetindene maleate) is officially documented by government regulatory authorities, detailing adverse reactions primarily related to the Central Nervous System.

The most frequent effects listed are Fatigue, classified as Very Common in official documents, and Drowsiness (Sedation), classified as Common. Drowsiness is noted as occurring in particular at the start of treatment. Other Common effects include Nervousness. Rare adverse reactions include Headache, Dizziness, and Agitation, along with Gastrointestinal Disorders such as Nausea and Dry mouth/throat.

Serious Adverse Reactions and Systemic Safety

Regulatory documents list the potential for Anaphylactic reaction in the Very Rare frequency class. This serious systemic reaction can include severe symptoms such as facial oedema, difficulty breathing (dyspnoea), and muscle spasms.

Population-Specific Safety Considerations

The medicine is contraindicated in neonates under one month of age, including premature babies. Caution is required when used in infants between one month and one year due to the potential association between the sedative effect and sleep apnoea. Additionally, the official safety labeling advises caution in elderly patients and individuals with certain pre-existing conditions, including glaucoma, epilepsy, and conditions leading to urinary retention or COPD (Chronic Obstructive Pulmonary Disease).

Feniallerg can also cause a drop in concentration, a safety limitation that requires awareness when performing tasks such as operating machinery or driving.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Feniallerg (dimetindene maleate) based on documented clinical manifestations and mandated emergency actions.

Documented Overdose Manifestations

Overdosage primarily affects the Central Nervous System (CNS) and cardiovascular system, with presentations varying by age. In children, symptoms are often characterized by CNS stimulation, including excitement, hallucinations, and spasms (seizures). Conversely, adults typically present with signs of CNS depression, such as drowsiness, somnolence, which can progress to coma. Antimuscarinic effects, including dry mouth and mydriasis (dilated pupils), are also documented.

Required Emergency Actions

Immediate medical attention must be sought following any suspected overdosage. The presence of severe manifestations, such as seizures, profound hypotension, or signs of cardiorespiratory collapse, requires urgent contact with emergency services. Regulatory guidance confirms that no specific antidote is known for this compound; therefore, treatment relies on symptomatic and supportive measures. These procedures, described in official labeling, may include gastric lavage, administration of activated charcoal, and mandatory cardiac monitoring to manage potential cardiovascular complications.

Therapeutic Uses of Feniallerg

What Feniallerg Treats: Main Uses and Benefits

Feniallerg (dimetindene maleate) is commonly used to help with symptomatic relief across therapeutic domains involving heightened physiological activity. The drug is indicated for allergic reactions and pruritus of various origins, which contributes to improved day-to-day comfort by offering short-term supportive assistance when symptoms interfere with daily functioning.

The medication is applied in addressing symptom clusters dominated by generalized or localized itching (pruritus), redness, and temporary tissue swelling. It is commonly used for conditions such as urticaria (hives), allergic rhinitis (including hay fever), pruritic dermatoses, and the itching associated with insect bites and chickenpox.

Feniallerg is relevant for easing both the pronounced pruritus linked to acute skin manifestations and the symptoms that interfere with daily functioning in the upper respiratory area associated with seasonal allergies. This approach supports a more manageable experience during acute episodes and provides supportive relief in specific situations where itching is a pronounced symptom.

The primary focus is on Pruritus and Allergic Symptoms

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Feniallerg — official regulatory information

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Oral Drops: Adults and children over 1 year of age. Topical Gel: Adults, the elderly, and children aged 2 years or over.
Populations for whom use is not recommended (if applicable)	Lactating (Breastfeeding) mothers (Oral Drops). Infants from 1 month to 1 year (Oral Drops) unless under medical advice. Confused elderly patients (Oral Drops).
Populations for whom use is contraindicated	Newborn babies less than 1 month old, especially premature infants (Oral Drops). Patients with known hypersensitivity to dimetindene maleate or any excipients.
Age-related eligibility rules	Minimum age for Oral Drops is 1 month, but restricted (see above). Minimum age for Topical Gel is 2 years.
Condition-specific eligibility rules	Use requires caution in patients with glaucoma (narrow-angle), urinary retention (e.g., prostatic hypertrophy), COPD, and epilepsy.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Oral drops only to be used under a strict indication. Topical gel not to be applied to large areas of skin. Lactation: Oral drops not recommended; topical gel must not be applied to the nipples.

Eligibility classifications (high-level)

Category	Classification
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute Prohibition), Not Recommended (Avoidance/Restriction), Caution Required (Conditional Use).

Connection to the overall eligibility profile

Governmental regulatory documents strictly define who can and cannot use Feniallerg by establishing formal contraindications based on age (newborns) and hypersensitivity. Use is further restricted to conditional status for populations like infants (1 month to 1 year), pregnant women, and breastfeeding mothers, requiring caution or medical supervision to maintain regulatory compliance. This profile also mandates caution for patients with pre-existing conditions like glaucoma or COPD.

What should I know about interactions with other medicines?

Feniallerg (dimetindene maleate) interaction information is based exclusively on additive pharmacological effects documented in official government regulatory texts. No specific pharmacokinetic mechanisms, such as CYP enzyme inhibition or transporter effects, are explicitly described in the prescribing information. The interaction profile is defined by restrictions against medicinal products that enhance the drug's primary activities.

Interacting Substance/Class	Official Regulatory Statement	Interaction Constraint
CNS Depressants (including sedatives, hypnotics, and other antihistamines)	Concomitant use is documented to result in an enhanced sedative effect or potentiation of CNS depression.	Use with Caution
Alcohol	Officially stated to increase the sedative effects of the medicine, potentially slowing down reflexes.	Avoid/Limit Use
MAO Inhibitors (Monoamine Oxidase Inhibitors)	Co-administration is not recommended due to the enhanced anticholinergic and antihistaminic effects.	Use with Restriction
Anticholinergic Agents	Causes an additive anticholinergic effect, increasing the potential for adverse outcomes such as urinary retention.	Use with Caution

The official profile includes two additional constraints. Due to the low systemic absorption of the topical gel formulation, systemic interactions with other medicinal products are not expected. Furthermore, regulatory texts highlight a specific population-based concern: the sedative effect is associated with a risk of sleep apnea when administering oral drops to infants under one year, which requires specialized caution when considering co-administration. No mandatory timing separation rules are documented.

Mechanism of Action

Blocking the Action of Histamine

Feniallerg's primary mechanism involves acting as an inverse agonist/antagonist at the Histamine H1 receptors located on various cell surfaces, predominantly in peripheral tissues. By binding to the H1 receptor, the drug stabilizes its inactive conformation, which prevents the chemical messenger histamine from initiating its signaling cascade. This molecular blockade acts to inhibit the biological signaling mediated by histamine.

Modulating Vascular and Tissue Responses

The interruption of the histamine-mediated cascade leads to a physiological modulation within the vascular system. Activation of the H1 receptor typically influences the permeability of small blood vessels; consequently, the drug's mechanism alters the dynamics of fluid movement across the vessel walls. This limits the change in local tissue volume and modifies sensory nerve signaling that is dependent on H1 receptor activation. The mechanism is characterized as a peripheral action pattern that targets mediator-driven physiological activity.

Dosage and Administration Information

The administration of Feniallerg (dimetindene maleate) is governed by its specific drug form, utilizing either the oral route for systemic action via drops or the topical route for localized cutaneous application. The medicine is available as oral drops (solution) at a concentration of 1 mg/ml or as a 0.1% topical gel.

Dosing and Frequency

For adults, the standard oral regimen involves a total daily dose of 3 mg to 6 mg, which is typically administered in three divided doses throughout the day. An officially defined adjusted schedule may be used for patients susceptible to drowsiness, providing the larger portion (40 drops) at bedtime and the smaller portion (20 drops) at breakfast. For the pediatric population, the oral dose is weight-based, with a typical recommended daily intake of 0.1 mg/kg, divided into three administrations.

The topical gel is intended for intermittent use, applied as a thin layer and lightly massaged onto the affected area two to four times daily.

Administration Constraints and Duration

The oral drops should be administered undiluted, or if mixed, added to lukewarm liquid immediately prior to consumption; they must not be added to hot liquids. The vial must be held vertically to ensure accurate drop counting. Labeling establishes constraints on duration: self-treatment with the oral drops should not exceed 14 days, and topical gel use should not exceed 7 days, without seeking medical guidance. For infants under one year, use of the oral drops requires strict medical indication. Topical gel application must be avoided on large or broken skin areas in young children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Feniallerg

Evidence for Symptomatic Relief of Acute Pruritus and Urticaria

Research involving oral Feniallerg has primarily focused on Randomized Controlled Trials (RCTs) and double-blind, placebo-controlled designs. These trials were typically conducted during episodes where symptoms become more noticeable, exploring short-term symptom patterns in adults diagnosed with acute or chronic spontaneous urticaria (hives), as well as in volunteer subjects where pruritus (itching) was observed in experimental settings.

Studies monitored several outcomes related to physical discomfort, including the measurement of changes in reported pruritus severity scores and objective assessments of wheal dimensions. Data show patterns related to measured short-term outcomes against placebo that were generally observed across the studies. However, follow-up durations were limited in many of the key efficacy trials, meaning long-term effects are not fully established.

Evidence for Symptomatic Relief in Allergic Rhinitis (Hay Fever)

Research for the symptomatic use of Feniallerg in allergic rhinitis (hay fever) includes controlled studies, some of which were conducted in research contexts involving fluctuating or unstable symptoms, such as under specific allergen challenge conditions. These studies explored how outcomes related to systemic or functional imbalance were measured in adults and children affected by seasonal pollen allergies.

Data show patterns related to how patient-reported outcomes describing perceived discomfort changed during the short period of observation in these research scenarios. Evidence concerning the durability of response or the sustained effects across a full, varied allergy season is limited. Furthermore, comparative evidence is lacking against the most recently developed antihistamine agents in large-scale modern studies.

Evidence for Topical Use in Localized Pruritus and Skin Reactions

The research structure for the topical gel formulation includes double-blind, placebo-controlled trials, frequently using experimental methods like histamine-induced weal and flare to examine short-term symptom patterns under standardized conditions. This research was also evaluated in children with acute eruptive skin diseases, such as chickenpox.

Studies monitored outcomes linked to inflammatory or irritative states, specifically examining the change in the skin's itch threshold and objective assessment of weal and flare reaction dimensions. As the studies mainly involve single application or very short observation times, the follow-up durations were limited and sample sizes were modest in some older localized studies. Data for certain groups remain insufficient, meaning the results apply only to the populations studied within the existing trial data.

Frequently Asked Questions (FAQ)

Common questions about Feniallerg (FAQ)

Q: Is Feniallerg available over-the-counter or is it prescription-only?

The availability status of Feniallerg as an over-the-counter (OTC) or prescription-only medicine varies depending on the country and the specific drug form. In many regulatory regions, the active ingredient is available for short-term self-treatment. However, use in specific patient populations, such as infants under one year of age, is typically subject to prescription requirements.

Q: How quickly does Feniallerg start to work after taking it?

Regulatory data indicate that the active substance is rapidly absorbed following oral administration. As a first-generation antihistamine, its antihistamine action is associated with rapid absorption, aligning with its purpose of symptomatic relief.

Q: How long does the effect of Feniallerg usually last?

Official information on the drug's properties states that the elimination half-life of the active ingredient, dimetindene, generally ranges from 4 to 6 hours in the body. This measurement provides insight into the typical duration of the medicine’s activity in the body.

Q: Does Feniallerg cause dry mouth or dry eyes?

According to the official product information, dry mouth or throat is listed as a rare possible adverse reaction. The official documentation lists this as a rare adverse reaction. While dry eyes are not specifically listed, the overall incidence of dry-related effects is low.

Q: What food or drinks should be avoided while using Feniallerg?

Regulatory documents contain an instruction to avoid or limit the consumption of alcohol due to the documented potential for enhanced sedative effects. Furthermore, if you are mixing the oral drops, administration instructions specify that they should not be added to hot liquids.

Q: Can I drink coffee while taking Feniallerg?

The official interaction profile focuses on substances that increase the drug's sedative effect, known as CNS Depressants. Caffeine, a central nervous system stimulant, is not explicitly listed in the regulatory warnings. However, the interaction profile focuses on CNS depressants, and caution concerning the use of stimulants, such as caffeine, is warranted.

Q: Can I cut or crush Feniallerg tablets?

The officially regulated product forms are the oral drops (solution) and the topical gel. For the oral drops, administration instructions state that they should be administered undiluted or mixed with lukewarm liquid immediately before consumption. The product is not supplied in a tablet form that can be cut or crushed.

Q: Can Feniallerg be taken on an empty stomach?

The active ingredient is rapidly absorbed through the digestive system. Official regulatory texts indicate that while the presence of food may slightly delay the speed of absorption, it does not significantly change the total amount of the drug that reaches the bloodstream.

Q: Is Feniallerg approved by the FDA/EMA for its uses?

The active ingredient, dimetindene maleate, is subject to regulation by governmental agencies, including those associated with the FDA and EMA. It has regulatory identifiers from both the US Food and Drug Administration (FDA) and the European Chemicals Agency (EC), and its approved uses are detailed in official regulatory documents worldwide.

Q: What should I do if I suspect an allergic reaction to Feniallerg itself?

Official regulatory documents classify a severe systemic allergic reaction, known as Anaphylactic reaction, as a very rare possible adverse event. If signs of a serious reaction occur, such as facial swelling, hives, or difficulty breathing, Official safety information requires that immediate medical attention be sought.

Q: Is there a risk of overdose with Feniallerg?

Regulatory documents confirm that like all medications, the safety profile documents the potential for overdose. This information includes the signs and symptoms associated with taking quantities that exceed the officially specified dose.

Q: Is it true that Feniallerg can interact with certain antidepressants?

Official regulatory documents state that co-administration with MAO Inhibitors (a class of antidepressants) is not recommended due to enhanced effects. Caution is also required for other medications that have anticholinergic or CNS depressant activity, which may include certain other types of antidepressants.

Q: Does Feniallerg have any known effects on blood pressure?

Effects on blood pressure are not listed as a common side effect of the medicine. However, regulatory documents for H1 antagonists indicate that changes in the cardiovascular system, such as low blood pressure (hypotension), are a possible feature of an overdose. The official safety profile mandates caution for patients who have pre-existing cardiovascular conditions.

Q: What is the evidence supporting the use of Feniallerg in chronic conditions?

Official regulatory texts describe that research has primarily focused on short-term outcomes during acute allergy episodes. Regulatory texts specifically note that the evidence for long-term effects is not fully established, as the key efficacy trials primarily involved limited follow-up durations.

How should Feniallerg be stored and disposed of?

Feniallerg (dimetindene maleate) must be stored and disposed of according to specific regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Requirement	Stated Condition
Temperature	Store at 15 C to 25 C; do not store above 25 C.
Protection	Must be protected from light and kept in the original packaging.
Child Safety	Keep out of the reach and sight of children.
Stability	Do not use after the expiry date printed on the package.

Disposal Instructions

Official labeling directs that Feniallerg must not be disposed of in waste water or household waste. Users are instructed to consult a pharmacist for the proper method of disposing of unused or expired medicine. Following general governmental guidelines, if no drug take-back option is available, the product should be mixed with an undesirable substance (like coffee grounds) and sealed before being placed in the trash.

Feniallerg